Skip to main content
. Author manuscript; available in PMC: 2010 Sep 29.
Published in final edited form as: J Neuroimmunol. 2009 Aug 6;214(1-2):67–77. doi: 10.1016/j.jneuroim.2009.06.023

Figure 7.

Figure 7

GPR30 agonist treatment inhibits inflammatory cytokine expression. Splenocytes from the individual mice analyzed in Figure 6 were re-stimulated with 50 μg/ml PLP139-151 peptide in vitro. Culture supernatants were harvested after 48 h and assessed for the presence of cytokines using Beadlyte Mouse Multi-cytokine Flex Kit assay. The data are shown as mean cytokine production (pg/ml from three individual mice ±SD) in cultures from G-1-treated mice compared to cells from control-treated mice. The results indicate significant (*, p<0.05) reductions in IFN-γ, TNF, IL-12, IL-17, CCL4, and CCL5 expression. The data are representative of two similar, independent experimental replicates.